Nanogen Licenses Gene Variants from Pathway Diagnostics for Dx Predicting Drug Response | GenomeWeb

NEW YORK, March 22 (GenomeWeb News) - Nanogen has licensed genetic variations from Pathways Diagnostics that predict patients' response to antidepressants and antipsychotic in order to create a diagnostic product, the company said today.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.